Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589624 · ClinicalTrials.gov registry record · Phase 1
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
A Phase 1 study of Thyroid Gland Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04589624: Recruiting Phase 1 study of Thyroid Gland Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT04589624 is a Phase 1 study of Thyroid Gland Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants, below the 783-participant average among 3 other Thyroid Gland Carcinoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04589624, a Phase 1 study of Thyroid Gland Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.
Primary Outcome
To measure metabolic imaging data or information derived from hyperpolarized pyruvate MRI (hpMRI) that can be used to identify an early indication of response to therapy in patients with thyroid cancer. Specifically, we measure the kPL-the apparent rate constant for conversion of HP pyruvate into lactate-after one week of treatment compared to baseline measurements acquired prior to start of therapy. The kPL will be calculated from dynamic images of HP pyruvate and its metabolites. The kPL value
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Hyperpolarized Carbon C 13 Pyruvate
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
What NCT04589624 shows while recruiting
NCT04589624 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 783-participant average among 3 other Thyroid Gland Carcinoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT04589624 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04589624 about?
NCT04589624 is a clinical study titled "An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy". This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI ...
What is the current status of trial NCT04589624?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-08-12. Estimated completion is 2027-05-31.
What conditions does trial NCT04589624 study?
This clinical trial studies the following conditions: Thyroid Gland Carcinoma.
What interventions are being tested in trial NCT04589624?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04589624?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04589624 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
RECRUITING
-
Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
RECRUITING
-
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI